Altria Group acquired a 45% stake in Cronos Group, a leading global cannabinoid company, headquartered in Toronto, for $1.8bn. “Investing in Cronos Group as our exclusive partner in the emerging global cannabis category represents an exciting new growth opportunity for Altria. We believe that Cronos Group’s excellent management team has built capabilities necessary to compete globally, and we look forward to helping Cronos Group realize its significant growth potential.” Howard Willard, Altria Chairman and Chief Executive Officer.